Morgan Stanley Cuts Price Target on Rubius Therapeutics to $1.50 From $2, Maintains Equalweight Rating
Morgan Stanley Cuts Price Target on Rubius Therapeutics to $1.50 From $2, Maintains Equalweight Rating
摩根士丹利将Rubius Therapeutics的目标股价从2美元下调至1.50美元，维持同等权重评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间